4582 Stock Overview
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities in the areas of oncology and hematology in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SymBio Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥175.00 |
| 52 Week High | JP¥483.00 |
| 52 Week Low | JP¥173.00 |
| Beta | 0.72 |
| 1 Month Change | -5.91% |
| 3 Month Change | -22.91% |
| 1 Year Change | -56.47% |
| 3 Year Change | -86.68% |
| 5 Year Change | -77.21% |
| Change since IPO | -88.18% |
Recent News & Updates
Shareholder Returns
| 4582 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 0.6% | 0.5% | -0.5% |
| 1Y | -56.5% | 3.1% | 28.3% |
Return vs Industry: 4582 underperformed the JP Pharmaceuticals industry which returned 3.1% over the past year.
Return vs Market: 4582 underperformed the JP Market which returned 28.3% over the past year.
Price Volatility
| 4582 volatility | |
|---|---|
| 4582 Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.3% |
Stable Share Price: 4582's share price has been volatile over the past 3 months.
Volatility Over Time: 4582's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 109 | Fuminori Yoshida | www.symbiopharma.com |
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities in the areas of oncology and hematology in Japan and internationally. It offers SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, chronic lymphocytic leukemia, and relapsed/refractory diffuse large B-cell lymphoma; SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administrator under the TREAKISYM name. The company also engages in the development of SyB L-1101, an intravenous formulation, which completed Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase I/II clinical trial in combination with AZA to treat HR-MDS.
SymBio Pharmaceuticals Limited Fundamentals Summary
| 4582 fundamental statistics | |
|---|---|
| Market cap | JP¥8.02b |
| Earnings (TTM) | -JP¥1.96b |
| Revenue (TTM) | JP¥5.59b |
1.4x
P/S Ratio-4.1x
P/E RatioIs 4582 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4582 income statement (TTM) | |
|---|---|
| Revenue | JP¥5.59b |
| Cost of Revenue | JP¥1.18b |
| Gross Profit | JP¥4.41b |
| Other Expenses | JP¥6.37b |
| Earnings | -JP¥1.96b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
| Earnings per share (EPS) | -42.84 |
| Gross Margin | 78.91% |
| Net Profit Margin | -35.10% |
| Debt/Equity Ratio | 0% |
How did 4582 perform over the long term?
See historical performance and comparison